Northwest Biotherapeutics, Inc.
NWBO
$0.19
-$0.01-4.43%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.73% | 190.91% | -43.98% | -74.31% | 32.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.73% | 190.91% | -43.98% | -74.31% | 32.04% |
| Cost of Revenue | -41.83% | -47.22% | -8.36% | -10.41% | 5.15% |
| Gross Profit | 45.29% | 52.57% | 6.73% | 6.22% | -4.15% |
| SG&A Expenses | -29.98% | 5.06% | 0.60% | -22.74% | 15.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.58% | -24.31% | -4.21% | -17.05% | 10.34% |
| Operating Income | 37.03% | 27.00% | 3.25% | 15.37% | -9.95% |
| Income Before Tax | 84.13% | 103.02% | -38.48% | 13.94% | -5.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.13% | 104.92% | -38.48% | 13.94% | -5.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.13% | 104.92% | -38.48% | 13.94% | -5.63% |
| EBIT | 37.03% | 27.00% | 3.25% | 15.37% | -9.95% |
| EBITDA | 39.98% | 29.27% | 3.39% | 15.87% | -10.19% |
| EPS Basic | 85.42% | 103.67% | -17.42% | 26.49% | 9.43% |
| Normalized Basic EPS | 72.22% | 51.61% | -14.10% | 37.21% | 23.40% |
| EPS Diluted | 85.42% | 96.79% | 0.00% | 26.49% | 9.43% |
| Normalized Diluted EPS | 72.22% | 51.61% | -14.10% | 37.21% | 23.40% |
| Average Basic Shares Outstanding | 16.58% | 17.43% | 18.56% | 18.44% | 14.42% |
| Average Diluted Shares Outstanding | 16.58% | 17.43% | 18.56% | 18.44% | 14.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |